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Abstract: During a global research expedition, more than five hundred marine bacterial 
strains capable of inhibiting the growth of pathogenic bacteria were collected. The purpose 
of the present study was to determine if these marine bacteria are also a source of 
compounds that interfere with the agr quorum sensing system that controls virulence gene 
expression in Staphylococcus aureus. Using a gene reporter fusion bioassay, we recorded agr 
interference as enhanced expression of spa, encoding Protein A, concomitantly with reduced 
expression of hla, encoding α-hemolysin, and rnaIII encoding RNAIII, the effector molecule 
of agr. A marine Photobacterium produced compounds interfering with agr in S. aureus 
strain 8325-4, and bioassay-guided fractionation of crude extracts led to the isolation of 
two novel cyclodepsipeptides, designated solonamide A and B. Northern blot analysis 
confirmed the agr interfering activity of pure solonamides in both S. aureus strain 8325-4 
and the highly virulent, community-acquired strain USA300 (CA-MRSA). To our 
knowledge, this is the first report of inhibitors of the agr system by a marine bacterium. 
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1. Introduction  
Microorganisms are an attractive source of new natural products with antimicrobial properties [1,2], 
and the marine environment constitutes a prolific resource of bioactive microorganisms [3–5]. Many 
marine microenvironments stimulate the production of specific metabolites as a response to environmental 
factors [6]. It is likely that some of these metabolites mediate both intra- and interspecies microbial 
interactions, and can be seen as potential new scaffolds for development of drug lead candidates [6,7]. 
The increasing problem of antibiotic resistance among human pathogens highlights the need for novel 
therapeutic strategies [8]. The search for new avenues in microbial control has therefore been extended 
from traditional bacteriostatic or bacteriolytic compounds to compounds that target, for example, 
quorum sensing (QS) pathways [9–11]. Quorum sensing inhibitors (QSI) do not necessarily kill or 
inhibit the growth of a pathogen but rather modulate microbial phenotypes, for example by attenuating 
virulence [12,13]. In vivo studies with QS inhibitory compounds demonstrated how these can be used 
to slow the spread of infection [14] or enhance the clearance of pathogens from infected tissue [10]. 
Staphylococcus aureus is one of the main causes of nosocomial infections, and methicillin-resistant 
S. aureus (MRSA) are emerging at an alarming rate [15,16]. The virulence of S. aureus is ascribed to a 
number of virulence factors, including extracellular toxins such as α-hemolysin encoded by hla, and 
cell surface adhesion factors such as Protein A encoded by spa [17]. Their expression is coordinated 
through several key regulators, of which the agr (accessory gene regulator) QS system is central [18]. 
This system is a classical two-component system with a sensor histidine kinase, AgrC, and a response 
regulator, AgrA, in addition to AgrB and AgrD which are responsible for the production of the quorum 
sensing signal [19,20]. agr-dependent QS is mediated via autoinducing peptides (AIP), 16-membered 
thiolactone macrocycles carrying a peptide tail that control virulence gene expression through the 
effector molecule RNAIII [21,22]. Structure-activity relationship studies (SAR) demonstrated that 
while the tail of the AIP is essential for agr activation [19,23], the macrocyclic ring is responsible for 
antagonistic activity [23]. This has led to the synthesis of global inhibitors based on truncated 
AIPs  [23,24]; however, there are only few reports of natural antagonists of this system [24–27]. 
Nielsen et al. [28] recently developed a screening assay based on S. aureus lacZ reporter fusion strains, 
where the effect of compounds or extracts on expression of three key virulence genes (spa, hla, and 
rnaIII) and hence potential interference with the agr locus can be assessed. Subsequently, the assay 
was used to identify two xanthones as novel quorum sensing interfering compounds in S. aureus [28].  
We recently established a global collection of marine bacteria with antibacterial activity [29]. The 
purpose of the present study was to determine if this strain collection also harbored organisms that 
produced other types of bioactive compounds and we screened pure cultures, crude extracts, and purified 
secondary metabolites from the collection for potential inhibitors of the agr system. One of the bacterial 
families we investigated was the Vibrionaceae. These bacteria are ubiquitous in marine and brackish 
environments and often associated with marine organisms [30]. The Vibrionaceae consist of seven 
genera, with the majority of species belonging to the Vibrio and Photobacterium genera. Vibrio spp. can Mar. Drugs 2011, 9  
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be pathogenic to humans [31–33] or marine animals [30], but also occur in the commensal microflora of 
zooplankton [30] or live as bioluminescent symbionts with squid or fish [34–36]. The Photobacterium 
genus similarly comprises symbiotic [37,38] and pathogenic species [39–41]. Members of the 
Vibrionaceae produce broad-range inhibitory compounds [7,29]; however, only few of the antibacterial 
compounds have been isolated to date [42]. Antimicrobial compounds from Vibrio species include the 
pyrrolidinediones andrimid [43–45] and moiramide B [46] that inhibit fatty acid synthesis [47]. In 
addition, we recently reported the production of the potent pyrrothine antibiotic holomycin by a marine 
Photobacterium [45]. 
Herein, we report the isolation and chemical investigation of two novel depsipeptides produced by 
that same Photobacterium strain. The compounds, designated solonamides A and B, inhibit the agr QS 
system of S. aureus and therefore interfere with its virulence gene expression. This indicates that 
marine bacteria are a source of novel chemistry with potential use in antibacterial therapy. 
2. Results and Discussion  
2.1. Identification of QS Inhibitors from Photobacterium sp. 
In an initial search for antimicrobial compounds we isolated strain S2753 related to Photobacterium 
halotolerans [29]. Subsequently, the known antibiotic, holomycin, was identified as responsible for its 
growth inhibitory activity [45]. When investigating ethyl acetate extracts of S2753 in an agar diffusion 
assay monitoring expression of the S. aureus virulence genes hla, rnaIII, and spa [28], we observed an 
increased expression of spa and decreased expression of hla and rnaIII. The inverse effect of the extracts 
on spa and hla/rnaIII expression, respectively, indicates the presence of at least one compound that 
interferes with the S. aureus agr QS system [28]. Secondary screening of the extract by explorative 
solid-phase extraction (E-SPE) [48] detected the potential QSI activity in a fraction that did not inhibit 
growth of S. aureus or V. anguillarum (data not shown). Bioassay-guided fractionation by diol and  
C-18 columns resulted in the isolation of two compounds active in the S. aureus agar diffusion assay 
(Figure 1). The activity of the pure compounds matched the initial activity of the extract, confirming 
that these compounds are responsible for the observed changes in gene expression. 
Figure 1. Effect of solonamides (A and B) on hla, rnaIII and spa expression. Solonamides 
(5 mg mL
−1) were added to wells in TSA plates containing the 8325-4 derived lacZ reporter 
strains PC322 (hla::lacZ), SH101F7 (rnaIII::lacZ), or PC203 (spa::lacZ). Incubation time 
was 15 h for plate I and II, and 35 h for plate III (plate numbering indicated with white 
letters). Solonamide B tested in two wells. 
 
hla::lacZ rnaIII::lacZ spa::lacZ
A
B
B
DMSO
A
B
B
DMSO
A
B
B
DMSO
I II IIIMar. Drugs 2011, 9  
 
 
2540
2.2. Structural Elucidation of the Solonamides 
The solonamides were isolated as white powder with respective molecular formulas C30H46N4O6 (A) 
and C32H50N4O6 (B) as determined by HRMS (1 ppm mass accuracy). Analysis of NMR data 
characterized the structures of the solonamides as cyclodepsipeptides consisting of four amino acids 
and a 3-hydroxy fatty acid (Figure 2). The amino acid composition was elucidated as alanine, 
phenylalanine, and two leucines for both peptides based on DQF-COSY and HSQC NMR data. 
Figure 2. Structures of solonamides A and B produced by Photobacterium sp. strain S2753 
and structure of natural group I AIP [21]. 
A B 
 
I 
The spin systems of the amino acids were confirmed through strong and unambiguous H2BC 
correlations [49] and the carbonyl signals assigned by HMBC correlations. Through careful inspection of 
the DQF-COSY and H2BC NMR data, solonamide A was found to contain a 3-hydroxyhexanoic acid 
(Hha), while solonamide B contained a 3-hydroxyoctanoic acid (Hoa). Long-range HMBC and NOESY 
correlation data allowed the sequence of amino acids to be established as fatty acid-Phe-Leu-Ala-Leu 
(Figure in Supplementary Information). This was corroborated by MS-MS experiments giving the 
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in Leu and a weak NOESY correlation from H-3 to the Leu amide and Hα protons. In total, this 
accounted for the ten degrees of unsaturation resulting from the macrocyclic ring, five carbonyls, and 
the phenyl group. 
The absolute configurations of the individual amino acids were established by acid hydrolysis and 
Marfey’s method with UHPLC analysis. Both peptides were found to contain L-Phe, D-Ala, and an 
enantiomeric pair of L-Leu and D-Leu. Acid hydrolysis of the reduced linear peptides and subsequent 
Marfey’s derivatization specified the stereochemistry of the two Leu, exchanging the L-Leu peak   
(RT 3.77 min) with a new peak (RT 3.73 min), attributable to the corresponding alcohol. Thus, L- and  
D-stereochemistry was assigned as fatty acid-L-Phe-D-Leu-D-Ala-L-Leu in both solonamide A and B.  
The absolute configuration of the fatty acid was established by NMR spectroscopic analysis of the 
1H and 
19F chemical shift differences (Δδ
SR) in the (R)- and (S)-Mosher’s esters analysis of solonamide A 
and B. The absolute stereochemistry of C-3 in the 3-hydroxy fatty acid was established as (R) in both 
depsipeptides (Figure 3). 
Figure 3. Distribution of the Δδ values (ppm) calculated for the (a) 3-hydroxyhexanoic 
acid (Hha) and (b) 3-hydroxyoctanoic acid (Hoa) in the (R)- and (S)-Mosher’s esters. 
 
(a) 
 
(b) 
The yield of solonamides was up to 10 mg L
−1, which is a high organic yield compared to that of 
other  γ-proteobacteria [50,51]. This suggests that they could be storage compounds accumulated 
during growth. However, the solonamides were also produced on a chitin based minimal medium 
(Supplementary Information) which indicated that these compounds may be produced in the natural 
habitat of vibrios, such as chitinous zooplankton. In addition, D-alanine and L-leucine are incorporated 
in the structure; amino acids that are not present in the laboratory medium. Thus, the Photobacterium 
seems to produce these specific stereoforms rather than incorporating the available amino acids.  
2.3. Production of Solonamides by Related Photobacterium Strains 
To test whether the solonamides are also produced by strains related to our Photobacterium isolate, 
we compared strain S2753 with P. halotolerans LMG 22194
T,  P. rosenbergii LMG 22223
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P. angustum S14 [52]. None of these strains produced solonamides (as confirmed by LC-UV/MS), and 
none affected virulence gene expression in the gene-reporter agar diffusion assay. None of the three 
strains inhibited growth of V. anguillarum, and holomycin, the antibiotic of S2753 [45], was not detected.  
To the best of our knowledge, only two species of Photobacterium have been investigated for  
their secondary metabolites so far [51,53,54]. Oku et al. [51] isolated unnarmicin A and C from a 
marine Photobacterium strain MBIC06485 related to P. leiognathi. Like the solonamides, unnarmicin 
A and C consist of four amino acids (L-Phe,  L-Leu,  D-Phe,  L-Leu) and a 3-hydroxyoctanoic and   
3-hydroxyhexanoic fatty acid, respectively. The finding of the unnarmicins in another marine 
Photobacterium sp. indicates that production of such peptides could be a common feature in this group 
of bacteria, despite the absence of solonamides in any related strains that we investigated.  
2.4. Solonamides Interfere with agr 
To verify that the purified solonamides do in fact cause transcriptional changes in virulence gene 
expression and to assess if the effect is strain specific, we isolated mRNA from S. aureus 8325-4 and 
the community-acquired strain, USA300 at different stages of growth following solonamide exposure 
and monitored gene expression by Northern blot analysis. Solonamide B dramatically reduced the 
expression of both hla and rnaIII while increasing expression of spa, strongly indicating that the 
compound interferes with agr regulation (Figure 4). The decreased expression of rnaIII was even more 
pronounced in the highly virulent USA300 strain where high agr activity is suspected to be a main 
contributor to the virulence of the strain [55,56]. The solonamides did not affect the growth rate of the 
liquid S. aureus cultures. Solonamide A was able to increase spa expression, but caused only a marginal 
reduction of hla and rnaIII expression in both 8325-4 and USA300. The discrepancy between the 
Northern blot analysis and the agar diffusion assay (mainly with regard to hla) may be rooted in the 
much higher concentrations of solonamides that are used in the agar diffusion assay as compared to the 
Northern blot analysis. Also, the Northern blot analysis directly monitors the amount of mRNA shortly 
after solonamide addition, whereas the agar diffusion assay relies on the accumulation of β-galactosidase 
enzyme over a period of 15 or 35 h.  
The structural similarity of the solonamides and the AIPs (Figure 2) suggest that they may   
be competitive inhibitors of the agr system. Unlike the AIPs, the solonamides are cyclized through a  
3-hydroxy fatty acid forming a lactone rather than a thiolactone. However, synthetic lactone and 
lactam variations of natural AIPs have been found to have antagonistic activity [19,23,57], which our 
study corroborates. While inhibition of agr by AIPs is more tolerant of sequence and structural 
diversity than is activation [23], Mayville et al. [14] found that the presence of the hydrophobic leucine 
and phenylalanine residues is important for the inhibition of the agr response. Both solonamides 
contain a leucine and phenylalanine; however, the reduced activity of solonamide A indicates that the 
overall hydrophobicity of the depsipeptides affected by the varying length of the fatty acid moiety 
might be an important factor influencing activity.  
The solonamides are the first reported antagonists produced by a natural source with a structure 
resembling that of native S. aureus AIPs. Kiran et al. (2008) [25] identified hamamelitannin from 
Hamamelis virginiana (witch hazel) as an inhibitor of RNAIII and δ-hemolysin production in S. aureus 
8325-4, USA300, and clinical S. epidermidis isolate MH. Also, ambuic acid from an unidentified fungal Mar. Drugs 2011, 9  
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strain was found to attenuate agr [26].Given the relatively low abundance of staphylococci in the 
marine environment, it seems unlikely that the Photobacterium sp. S2753 produces solonamides as 
part of a deliberate strategy to interfere with this specific type of bacteria. However, the solonamides 
might be targeted at other Gram-positive bacteria in the marine environment, such as bacilli and 
actinobacteria, though little is known about quorum sensing pathways in marine Gram-positive 
bacteria. A large number of different QS systems have been characterized from Gram-negative 
bacteria in the marine environment [57–62]. We speculate that the solonamides could also affect such 
systems despite sharing little structural similarity to agonists and antagonists of the systems identified 
to date [63]. Acylated homoserine lactones, the most widely researched type of QS molecules in   
Gram-negatives, can serve as both agonists and antagonists in different systems [27], and thus the 
solonamides may also serve as quorum sensing signals for the Photobacterium itself. However, we did 
not detect solonamides or compounds with similar QSI activity in any of the related strains. 
Figure 4. Effect of solonamide A and B on virulence gene expression in S. aureus strain 
8325-4 [18] and USA300 [55] examined by Northern blot analysis. Solonamides were added 
to exponentially growing cultures at OD600 = 0.4, and RNA was purified at OD600 = 0.7 and 
1.7. The RNA was reacted with probes recognizing hla, rnaIII, and spa, respectively. 
Solonamide B tested in duplicates. DMSO was used as negative control. 
 
Our findings suggest that quorum sensing inhibition could be an alternative therapeutic strategy for 
treatment of MRSA S. aureus infections; however, the effect in an in vivo infection model needs to be 
tested. Many genes are under QS control both in Gram-positive and Gram-negative bacteria, and thus 
it is not a simple drug target [64,65]. For example, biofilm formation in S. aureus has been linked to 
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low QS activity [66], and so there is a risk that the use of QS inhibitors could lead to decreased 
susceptibility of traditional antibiotics. Also, it is still unknown how QS inhibition will affect the 
overall fitness of a pathogen under in vivo conditions and thus pose a selective pressure for 
development of resistance [67] or enhanced virulence [68,69]. 
3. Experimental Section 
3.1. Isolation and Identification of Strain S2753 
Bacterial strain S2753 was isolated from a mussel surface collected in the tropical Pacific (9.1°S 
156.8°E) during the Danish Galathea 3 expedition [29]. S2753 was assigned to the Vibrionaceae by 
16S rRNA gene sequence similarity [29] and identified as being closely related to Photobacterium 
halotolerans based on recA and rpoA  gene sequences, with homologies of 87% (recA) and 94% 
(rpoA) [45]. BLAST analyses showed that other closely related species were Photobacterium rosenbergii 
and Photobacterium angustum S14 [52].  
3.2. Initial Screening for Anti-Virulence Compounds 
S2753 was cultured in each 30 mL of (i) marine minimal medium (MMM) [70] containing 0.4% 
glucose and 0.3% casamino acids; (ii) Marine Broth 2216 (MB; Difco 2216); (iii) Sigma Sea Salts 
(SSS; Sigma S9883; 40 g L
−1) containing 0.4% glucose and 0.3% casamino acids, and (iv) MMM 
containing 0.2% colloidal chitin [71,72] to investigate the best conditions for production of antibacterial 
compounds. All cultures were incubated aerated (200 rpm) for 72 h at 25 °C. All cultures were extracted 
with an equal volume of ethyl acetate (EtOAc). The extract was evaporated under nitrogen until 
dryness and redissolved in 300 μL 80% v/v ethanol (EtOH) in water. 20 μL of the extract was tested in 
an agar diffusion assay where expression from promoters of hla, rnaIII, and spa is monitored [28].  
For further screening, the culture broth of S2753 grown in MMM (1 L, 72 h, 25 °C, 100 rpm) was 
extracted directly with sterile Diaion HP20SS (12 g L
−1, 24 h) (Sigma-Aldrich, St. Louis, MO). The 
resin was filtered off and washed with 80% (v/v) acetonitrile (MeCN)/water (300 mL) and the extract 
evaporated until dryness on a rotary evaporator. From this extract, 10 mg dry material was subjected to 
an explorative solid-phase extraction (E-SPE) protocol [48]. This yielded 15 fractions for re-testing in the 
agar diffusion assay as described above. The E-SPE fractions were also tested for antibacterial activity 
against Vibrio anguillarum strain 90-11-287 and S. aureus 8325 in a well diffusion agar assay [73].  
3.3. Isolation and Structural Elucidation of Solonamide A and B 
Using 10 L glass fermentors, S2753 was cultured in 5 × 4 L SSS (iii, above) containing 0.4% glucose 
and 0.3% casamino acids (25 °C, 72 h, 100 rpm) as this medium gave comparable yields to that of 
MMM (i) but at a lower cost. The broth was extracted directly with Diaion HP20SS (12 g L
−1) as 
described above. The extract (3.4 g) was redissolved in EtOAc, absorbed onto 5 g Isolute diol 
(Biotage, Uppsala, Sweden), and added to a glass column with pure diol (95 g). A total of 12 fractions 
were collected from the diol column (100 g, 20 × 350 mm) ranging from heptane, dichlormethane 
(DCM), EtOAc, to pure methanol (MeOH), running under gravity. The fractions containing the QSI 
compounds (fraction 5, 20:80 (v/v) EtOAc/DCM and fraction 6, 40:60 (v/v) EtOAc/DCM) were Mar. Drugs 2011, 9  
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separated on Sepra ZT C18 (Phenomenex, Torrance, CA)(10 g SNAP) on an Isolera automated flash 
system (Biotage) using a MeCN/water gradient 25–75% over 20 min (12 mL min
−1). Pure compounds 
were obtained directly: Solonamide A (17 mg) and B (201 mg). Activity of pure compounds was tested 
in the agar diffusion assay as described above (20 μL per well), with a final concentration of compounds 
of 5 mg mL
−1 in dimethyl sulfoxide (DMSO).  
NMR spectra were recorded on a Varian Unity Inova 500 MHz spectrometer equipped with a 5 mm 
probe using standard pulse sequences. The signals of the solvent were used as internal references  
(δH 2.49 and δC 39.5 ppm for DMSO). Carbonyl shifts were confirmed with 
13C 1D on a Bruker 
Avance 800 MHz spectrometer with a 5 mm TCI cryoprobe at the Danish Instrument Center for NMR 
Spectroscopy of Biological Macromolecules. 
LC-MS and LC-MS/MS analyses were performed on a maXis quadrupole time of flight mass 
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with an electrospray (ESI) ion source. 
The MS was connected to an Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA) equipped with a 
diode-array detector. Separation was performed at 40 °C on a 150 mm × 2.1 mm ID, 2.6 µm Kinetex 
C18 column (Phenomenex) using a linear water/MeCN (both buffered with 20 mM formic acid) gradient 
starting from 15% MeCN and increased to 100% in 13 min at a flow of 0.4 mL min
−1. The MS and 
MS/MS experiments were performed in ESI
+ with a data acquisition range of m/z 100–1200 with 
collision energy of 27 V. The MS was calibrated using sodium formate automatically infused prior to 
each analytical run, providing a mass accuracy of below 1 ppm in MS mode and 2 ppm in MS/MS mode.  
The absolute configuration of the amino acids were found using acid hydrolysis (6 M HCl,   
110 °C, 20 h) [74] and derivatisation with Marfey’s reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine  
amide, FDAA, Sigma-Aldrich) following the protocol by Bonnard et al. [75]. Ultra-high liquid 
chromatography-diode array (UHPLC-UV) analyses of the amino acids were done on a Dionex RSLC 
Ultimate 3000 (Dionex) equipped with a diode-array detector. Separation was obtained on a Kinetex 
C18 column (150 × 2.10 mm, 2.6 μm, Phenomenex) maintained at 60 °C using a linear gradient starting 
from 25% MeCN in water (both buffered with 50 ppm TFA) increasing to 27% MeCN over 6 min at a 
flow rate of 0.8 mL min
−1. Retention times of the FDAA amino acid derivatives used as standards were 
as follows (maximum standard deviation ± 0.002 min): FDAA (1.50 min), L-Ala (1.14 min), D-Ala 
(1.61 min), L-Phe (3.58 min), D-Phe (5.04 min), L-Leu (3.77 min), D-Leu (5.49 min), comparable to the 
observed retention times from the solonamide-derived amino acids.  
To specify the stereochemistry of enantiomeric amino acids, the depsipeptides were reduced by 
LiBH4. The resulting linear peptides were subjected to the above mentioned acid hydrolysis and 
Marfey’s derivatisation. Details are given in the Supplementary Information.  
For the absolute configuration of the fatty acid residues, the (R)- and (S)-Mosher’s esters were 
prepared for both depsipeptides, and the stereocenters were assigned based on their 
1H and 
19F chemical 
shift differences (Δδ
SR) [76,77]. Details are given in the Supplementary Information.  
Solonamide A: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 558.3486 (calcd for C30H46N4O6, 558.3496).  
Solonamide B: white amorphous solids; UV (MeCN/H2O) λmax 200 nm (100%); for NMR data refer 
to Table 1; HRESIMS m/z 586.3725 (calcd for C32H50N4O6, 586.3730).  
 Mar. Drugs 2011, 9  2546 
 
Table 1. NMR spectroscopic data (DMSO-d6) of solonamide A and B. 
  A  B 
  Atom  δC (ppm)  δH (ppm)(multiplicity, J (Hz))  HMBC  Atom  δC (ppm)  δH (ppm)(multiplicity, J (Hz))  HMBC 
Hha/Hoa 
1 170.6  -    1  170.4  -  - 
2  40.7  2.67 (1H, dd, 13.5, 3.8) 
2.11 (1H, dd, 13.5, 10.1) 
1,3,4  2  40.5  2.69 (1H, dd, 13.5, 3.7) 
2.11 (1H, dd, 13.5, 10.3) 
1,3,4 
3  72.1  5.14 (1H, m)  1,5  3  72.0  5.13 (1H, m)  1,4,5,36 
4  36.2  1.62 (1H, m) 
1.45 (1H, m) 
2,3,6  4  33.8  1.65 (1H, m) 
1.45 (1H, m) 
5,6 
5  17.7  ~1.22 (1H, m)  3,4  5  23.8  ~1.20 (2H, m)  6,7 
6  13.8  0.85 (3H, t, 7)  4,5  6  30.8  ~1.22 (2H, m)  ND 
        7  21.8  1.25 (2H, m)  ND 
        8  13.6  0.84 (3H, m)  6 
L-Phe 
7-NH  -  8.61 (1H, d, 3.2)  1  9-NH  -  8.59 (1H, d, 3.0)  1,10,11,8 
8-CHα  55.9  4.26 (1H, ddd, 10, 6.1, 3.2)  9,10,14  10-CHα  55.6  4.26 (1H, ddd, 10, 6.1, 3.3)  11,18 
9-CHβ,1  36.4  2.94 (1H, dd, 13.3, 6.1) 
2.72 (1H, dd, 13.3, 10) 
8,10,11/15,14 11-CHβ,1  36.1  2.95 (1H, dd, 13.3, 6.1) 
2.73 (1H, dd, 13.3, 10) 
10,12,13/17,18 
10 135.8  -  -  12  136.0  -  - 
11,15  129.1  7.18 (2H, m)  9,13  13,17 128.7 7.20  (2H,  m)  11,15 
12,14  128.4  7.25 (2H, m)  10  14,16 128.0 7.26  (2H,  m)  12,14/16 
13  126.5  7.18 (1H, m)  11  15  126.2  7.20 (1H, m)  13/17 
16-CO 174.4  -  -  18-CO  174.2  -  - 
D-Leu 
17-NH  -  8.63 (1H, d, 5.6)  16,18,19  19-NH  -  8.64 (1H, d, 5.6)  18,20,21 
18-CHα  53.1  3.56 (1H, m)  ND  20-CHα  52.7  3.57 (1H, m)  21,22,25 
19-CHβ,1  38.9  1.36 (1H, m) 
1.29 (1H, m) 
18,21,22 21-CHβ,1 38.6  1.31–1.37  (2H,  m)  20,22,24 
20-CHγ  23.5  0.97 (1H, m)  21  22-CHγ  23.3  0.99 (1H, m)  ND 
21-CHδ,1  23.2  0.69 (3H, d, 6.6)  19,20  23-CHδ,1  22.9  0.70 (3H, d, 6.6)  21,22,24 
22-CHδ,1  20.7  0.52 (3H, d, 6.5)  19,20  24-CHδ,1  20.4  0.53 (3H, d, 6.4)  21,23 
23-CO 171.8  -  -  25-CO  171.6  -  - 
D-Ala 
24-NH  -  7.53 (1H, d, 8.9)  27,29  26-NH  -  7.48 (1H, d, 8.9)  25,27,28 
25-CHα  48.2  4.18 (1H, m)  26,27  27-CHα  47.8  4.18 (1H, m)  28,29 
26-CHβ,1  16.6  1.32 (3H, d, 7.4)  27  28-CHβ,1  16.4  1.33 (3H, d, 7.3)  27,29 
27-CO 171.3  -  -  29-CO  170.9  -  - 
L-Leu 
28-NH  -  7.08 (1H, d, 10)  27,29  30-NH  -  7.05 (1H, d, 10)  29,31 
29-CHα  49.0  4.46 (1H, dt, 10, 4.4)  30,31,34  31-CHα  48.6  4.47 (1H, dt, 10, 4.3)  32,33,29/36 
30-CHβ,1  39.3  1.63 (1H, m) 
1.53 (1H, m) 
29,31,33,27/34 32-CHβ,1  39.0  1.64 (1H, m) 
1.52 (1H, m) 
31,33,35,29/36 
31-CHγ  23.9  1.50 (1H, m)  29,30,33  33-CHγ  23.8  1.50 (1H, m)  32,34,35 
32-CHδ,1  23.2  0.86 (3H, d, 6.5)  30,31,33  34-CHδ,1  23.0  0.86 (3H, d, 6.6)  32,33,35 
33-CHδ,1  21.3  0.81 (3H, d, 6.5)  30  35-CHδ,1  21.1  0.82 (3H, d, 6.4)  32,33 
34-CO 171.2  -  -  36-CO  170.8  -  - 
 Mar. Drugs 2011, 9  2547 
 
3.4. LC-UV/MS Analyses of Related Photobacterium Strains 
To investigate the potential production of agr inhibitors in related Photobacterium  strains, the 
metabolite profile of S2753 was compared by liquid chromatography-diode array/mass spectrometry 
(LC-UV/MS) to P. halotolerans (LMG 22194
T), P. rosenbergii (LMG 22223
T), and P. angustum (S14) 
described by de Nys et al. [52]. All strains were grown in 30 mL MMM containing 0.4% glucose and 
0.3% casamino acids (25 °C, 72 h, 200 rpm). Cultures were extracted with an equal volume of EtOAc 
and evaporated under nitrogen. Residues were redissolved in MeOH for LC-UV/MS analyses and in 
80% EtOH for bioassay testing. Inhibition of agr was tested as described above. Extracts were also 
tested against V. anguillarum strain 90-11-287 for growth inhibition. LC-UV/MS analyses were 
performed on an Agilent 1100 liquid chromatograph with a diode array detector (Agilent, Waldbronn, 
Germany) coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray 
ESI source. Separation was obtained on a Luna II C18 column (50 × 2 mm, 3 μm, Phenomenex) fitted 
with a security guard system using a linear gradient starting from 15% MeCN in water (both buffered 
with 20 mM formic acid) increasing to 100% MeCN over 20 min at a flow rate of 0.3 mL min
−1. 
3.5. Northern Blot Analysis 
Northern blot analysis was performed as described previously [78]. The strains used were S. aureus 
FPR 3757 [55], a CA-MRSA USA300 obtained from ATCC (Boras, Sweden), and 8325-4 [17]. Samples 
for RNA purification were taken from cultures in Tryptone Soya Broth (TSB, Oxoid, Greve, Denmark) 
shaking at 185 rpm at 37 °C in a water bath (10 mL culture in 100 mL Erlenmeyer flask). Growth was 
monitored by measuring optical density at OD600. Start inoculum was OD600 = 0.03. Solonamides were 
added at OD600 = 0.4. Samples for RNA purification were taken at OD600 = 0.7 and 1.7. Probes 
targeting rnaIII, spa, and hla transcripts were amplified by PCR using primers hla forward (5′-GGG 
TTA GCC TGG CCT TCA GCC-3′),  hla  reverse (5′-GGG TGC CAT ATA CCG GGT TC-3′),  
spa forward (5′-GGG GGT GTA GGT ATT GCA TCT G-3′), spa reverse (5′-GGG GCT CCT GAA 
GGA TCG TC-3′), rnaIII forward (5′-GGG GAT CAC AGA GAT GTG ATG-3′), and rnaIII reverse 
(5′-GGG CAT AGC ACT GAG TCC AAG G-3′)(TAG Copenhagen A/S, Denmark). The resulting 
PCR fragments were 311 bp (hla), 719 bp (spa), and 316 bp (rnaIII), respectively.  
4. Conclusions  
The rapid, worldwide increase in antibiotic-resistant S. aureus [15] has led to an intense search for 
compounds with potential use in alternative therapeutic strategies [9]. Virulence of S. aureus involves 
a complex set of proteins, with the agr QS system controlling expression of several of the virulence 
genes. The investigation of crude extracts and fractions from a marine Photobacterium led to the 
identification of two novel depsipeptides, solonamides A and B, as potent inhibitors of this system. 
Interestingly, we found that solonamide B interfered with agr not only in S. aureus 8325-4 but also in 
strain USA300, which is a predominant community-acquired MRSA (CA-MRSA) strain in the US [79]. 
This finding suggests that quorum sensing inhibition could be an option for treatment of S. aureus 
USA300 infections. Future experiments will reveal the extent to which the solonamides are effective in 
treating S. aureus infections. In combination with other recent work from our laboratory [42,45,71]  Mar. Drugs 2011, 9  
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the present study underlines that vibrios are a promising potential source of novel bioactive 
secondary metabolites.  
Acknowledgments 
We thank Anita Iversen for ultra high-resolution MS data and the Danish Center for NMR 
Spectroscopy of Biological Macromolecules for NMR time. Funding from the Programme Committee 
for Food, Health and Welfare under the Danish Strategic Research Council is acknowledged. The 
present work was carried out as part of the Galathea 3 expedition under the auspices of the Danish 
Expedition foundation. This is Galathea 3 contribution p85. 
References 
1.  Berdy, J. Bioactive microbial metabolites—A personal view. J. Antibiot. 2005, 58, 1–26. 
2.  Clardy, J.; Fischbach, M.A.; Walsh, C.T. New antibiotics from bacterial natural products. Nat. 
Biotechnol. 2006, 24, 1541–1550. 
3.  Das, S.; Lyla, P.S.; Khan, S.A. Marine microbial diversity and ecology: Importance and future 
perspectives. Curr. Sci. 2006, 90, 1325–1335. 
4.  Gulder, T.A.M.; Moore, B.S. Chasing the treasures of the sea—Bacterial marine natural products. 
Curr. Opin. Microbiol. 2009, 12, 252–260. 
5.  Rahman, H.; Austin, B.; Mitchell, W.J.; Morris, P.C.; Jamieson, D.J.; Adams, D.R.; Spragg, A.M.; 
Schweizer, M. Novel anti-infective compounds from marine bacteria. Mar. Drugs 2010, 8, 498–518. 
6.  de Carvalho, C.C.C.R.; Fernandes, P. Production of metabolites as bacterial responses to the 
marine environment. Mar. Drugs 2010, 8, 705–727. 
7.  Long, R.A.; Azam, F. Antagonistic interactions among marine pelagic bacteria. Appl. Environ. 
Microbiol. 2001, 67, 4975–4983. 
8.  Wright, G.D.; Sutherland, A.D. New strategies for combating multidrug-resistant bacteria. Trends 
Mol. Med. 2007, 13, 260–267. 
9.  Clatworthy, A.E.; Pierson, E.; Hung, D.T. Targeting virulence: A new paradigm for antimicrobial 
therapy. Nat. Chem. Biol. 2007, 3, 541–548. 
10.  Rasmussen, T.B.; Givskov, M. Quorum-sensing inhibitors as anti-pathogenic drugs. Int. J. Med. 
Microbiol. 2006, 296, 149–161. 
11.  Sintim, H.O.; Al Smith, J.; Wang, J.X.; Nakayama, S.; Yan, L. Paradigm shift in discovering 
next-generation anti-infective agents: Targeting quorum sensing, c-di-gmp signaling and biofilm 
formation in bacteria with small molecules. Future Med. Chem. 2010, 2, 1005–1035. 
12.  Bjarnsholt, T.; Givskov, M. Quorum-sensing blockade as a strategy for enhancing host defences 
against bacterial pathogens. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2007, 362, 1213–1222. 
13.  Camara, M.; Williams, P.; Hardman, A. Controlling infection by tuning in and turning down the 
volume of bacterial small-talk. Lancet Infect. Dis. 2002, 2, 667–676. 
14. Mayville, P.; Ji, G.Y.; Beavis, R.; Yang, H.M.; Goger, M.; Novick, R.P.; Muir, T.W.   
Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus 
aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 1999, 96, 1218–1223. Mar. Drugs 2011, 9  
 
 
2549
15.  Grundmann, H.; Aires-De-Sousa, M.; Boyce, J.; Tiemersma, E. Emergence and resurgence of 
meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368, 874–885. 
16.  Hiramatsu, K.; Cui, L.; Kuroda, M.; Ito, T. The emergence and evolution of methicillin-resistant 
Staphylococcus aureus. Trends Microbiol. 2001, 9, 486–493. 
17.  Chan, W.C.; Coyle, B.J.; Williams, P. Virulence regulation and quorum sensing in staphylococcal 
infections: Competitive agrc antagonists as quorum sensing inhibitors. J. Med. Chem. 2004, 47, 
4633–4641. 
18. Novick, R.P.; Morse, S.I. In vivo transmission of drug resistance factors between strains of 
Staphylococcus aureus. J. Exp. Med. 1967, 125, 45–59. 
19.  McDowell, P.; Affas, Z.; Reynolds, C.; Holden, M.T.G.; Wood, S.J.; Saint, S.; Cockayne, A.;  
Hill, P.J.; Dodd, C.E.R.; Bycroft, B.W.; Chan, W.C.; Williams, P. Structure, activity and 
evolution of the group i thiolactone peptide quorum-sensing system of Staphylococcus aureus. 
Mol. Microbiol. 2001, 41, 503–512. 
20.  Novick, R.P. Autoinduction and signal transduction in the regulation of staphylococcal virulence. 
Mol. Microbiol. 2003, 48, 1429–1449. 
21.  Ji, G.Y.; Beavis, R.C.; Novick, R.P. Cell density control of staphylococcal virulence mediated by 
an octapeptide pheromone. Proc. Natl. Acad. Sci. USA 1995, 92, 12055–12059. 
22.  Ji, G.Y.; Beavis, R.; Novick, R.P. Bacterial interference caused by autoinducing peptide variants. 
Science 1997, 276, 2027–2030. 
23.  Lyon, G.J.; Wright, J.S.; Muir, T.W.; Novick, R.P. Key Determinants of Receptor Activation in 
the Agr Autoinducing Peptides of Staphylococcus aureus. Biochemistry 2002, 41, 10095–10104. 
24.  Muir, T.W. Turning virulence on and off in staphylococci. J. Pept. Sci. 2003, 9, 612–619. 
25.  Kiran, M.D.; Adikesavan, N.V.; Cirioni, O.; Giacometti, A.; Silvestri, C.; Scalise, G.; Ghiselli, R.; 
Saba, V.; Orlando, F.; Shoham, M.; Balaban, N. Discovery of a quorum-sensing inhibitor of  
drug-resistant staphylococcal infections by structure-based virtual screening. Mol. Pharmacol. 
2008, 73, 1578–1586. 
26.  Nakayama, J.; Uemura, Y.; Nishiguchi, K.; Yoshimura, N.; Igarashi, Y.; Sonomoto, K. Ambuic 
acid inhibits the biosynthesis of cyclic peptide quormones in gram-positive bacteria. Antimicrob. 
Agents Chemother. 2009, 53, 580–586. 
27.  Qazi, S.; Middleton, B.; Muharram, S.H.; Cockayne, A.; Hill, P.; O’Shea, P.; Chhabra, S.R.; 
Camara, M.; Williams, P. N-acylhomoserine lactones antagonize virulence gene expression and 
quorum sensing in Staphylococcus aureus. Infect. Immun. 2006, 74, 910–919. 
28.  Nielsen, A.; Nielsen, K.F.; Frees, D.; Larsen, T.O.; Ingmer, H. Method for screening compounds 
that influence virulence gene expression in Staphylococcus aureus. Antimicrob. Agents Chemother. 
2010, 54, 509–512. 
29. Gram, L.; Melchiorsen, J.; Bruhn, J.B. Antibacterial activity of marine culturable bacteria 
collected from a global sampling of ocean surface waters and surface swabs of marine organisms. 
Mar. Biotechnol. 2010, 12, 439–451. 
30.  Thompson, F.L.; Iida, T.; Swings, J. Biodiversity of vibrios. Microbiol. Mol. Biol. Rev. 2004, 68, 
403–435. 
31.  Faruque, S.M.; Albert, M.J.; Mekalanos, J.J. Epidemiology, genetics, and ecology of toxigenic 
Vibrio cholerae. Microbiol. Mol. Biol. Rev. 1998, 62, 1301–1314. Mar. Drugs 2011, 9  
 
 
2550
32.  Linkous, D.A.; Oliver, J.D. Pathogenesis of Vibrio vulnificus. FEMS Microbiol. Lett. 1999, 174, 
207–214. 
33.  Su, Y.C.; Liu, C.C. Vibrio parahaemolyticus: A concern of seafood safety. Food Microbiol. 2007, 
24, 549–558. 
34.  Fidopiastis, P.M.; von Boletzky, S.; Ruby, E.G. A new niche for Vibrio logei, the predominant 
light organ symbiont of squids in the genus Sepiola. J. Bacteriol. 1998, 180, 59–64. 
35. Haygood, M.G.; Distel, D.L. Bioluminescent symbionts of flashlight fishes and deep-sea 
anglerfishes form unique lineages related to the genus Vibrio. Nature 1993, 363, 154–156. 
36. Ruby, E.G. Lessons from a cooperative, bacterial-animal association: The Vibrio fischeri 
Euprymna scolopes light organ symbiosis. Annu. Rev. Microbiol. 1996, 50, 591–624. 
37. Ast, J.C.; Dunlap, P.V. Phylogenetic resolution and habitat specificity of members of the 
Photobacterium phosphoreum species group. Environ. Microbiol. 2005, 7, 1641–1654. 
38.  Boisvert, H.; Chatelai, R.; Bassot, J.M. Studies on a Photobacterium isolated from light organ of 
fish Leiognathidae. Ann. Inst. Pasteur 1967, 112, 521–525. 
39. Magarinos, B.; Romalde, J.L.; Lopez-Romalde, S.; Morinigo, M.A.; Toranzo, A.E. Pathobiological 
characterisation of Photobacterium damselae subsp piscicida isolated from cultured sole (Solea 
senegalensis). Bull. Eur. Assoc. Fish Pathol. 2003, 23, 183–190. 
40. Thompson, F.L.; Thompson, C.C.; Naser, S.; Hoste, B.; Vandemeulebroecke, K.; Munn, C.; 
Bourne, D.; Swings, J. Photobacterium rosenbergii sp. nov. and Enterovibrio coralii sp. nov., 
vibrios associated with coral bleaching. Int. J. Syst. Evol. Microbiol. 2005, 55, 913–917. 
41. Richards, G.P.; Watson, M.A.; Crane, E.J., III; Burt, I.G.; Bushek, D. Shewanella  and 
Photobacterium spp. in oysters and seawater from delaware bay. Appl. Environ. Microbiol. 2008, 
74, 3323–3327. 
42.  Mansson, M.; Gram, L.; Larsen, T.O. Production of bioactive secondary metabolites by marine 
Vibrionaceae. Mar. Drugs 2011, 9, 1440–1468. 
43. Long,  R.A.; Rowley, D.C.; Zamora, E.; Liu, J.Y.; Bartlett, D.H.; Azam, F. Antagonistic interactions 
among marine bacteria impede the proliferation of Vibrio cholerae. Appl. Environ. Microbiol. 
2005, 71, 8531–8536. 
44. Oclarit, J.M.; Okada, H.; Ohta, S.; Kaminura, K.; Yamaoka, Y.; Iizuka, T.; Miyashiro, S.;   
Ikegami, S. Anti-bacillus substance in the marine sponge, hyatella species, produced by an 
associated Vibrio species bacterium. Microbios 1994, 78, 7–16. 
45.  Wietz, M.; Mansson, M.; Gotfredsen, C.H.; Larsen, T.O.; Gram, L. Antibacterial compounds 
from marine Vibrionaceae isolated on a global expedition. Mar. Drugs 2010, 8, 2946–2960. 
46.  Needham, J.; Kelly, M.T.; Ishige, M.; Andersen, R.J. Andrimid and moiramides A–C, metabolites 
produced in culture by a marine isolate of the bacterium Pseudomonas fluorescens—Structure 
elucidation and biosynthesis. J. Org. Chem. 1994, 59, 2058–2063. 
47.  Pohlmann, J.; Lampe, T.; Shimada, M.; Nell, P.G.; Pernerstorfer, J.; Svenstrup, N.; Brunner, N.A.; 
Schiffer, G.; Freiberg, C. Pyrrolidinedione derivatives as antibacterial agents with a novel mode 
of action. Bioorg. Med. Chem. Lett. 2005, 15, 1189–1192. 
48.  Mansson, M.; Phipps, R.K.; Gram, L.; Munro, M.H.G.; Larsen, T.O.; Nielsen, K.F. Explorative 
Solid-Phase Extraction (E-SPE) for accelerated microbial natural product discovery, dereplication, 
and purification. J. Nat. Prod. 2010, 73, 1126–1132. Mar. Drugs 2011, 9  
 
 
2551
49. Nyberg, N.T.; Duus, J.O.; Sorensen, O.W. Heteronuclear two-bond correlation: Suppressing 
heteronuclear three-bond or higher nmr correlations while enhancing two-bond correlations even 
for vanishing (2)J(CH). J. Am. Chem. Soc. 2005, 127, 6154–6155. 
50.  Fenical, W. Chemical studies of marine-bacteria—Developing a new resource. Chem. Rev. 1993, 
93, 1673–1683. 
51. Oku, N.; Kawabata, K.; Adachi, K.; Katsuta, A.; Shizuri, Y. Unnarmicins A and C, new 
antibacterial depsipeptides produced by marine bacterium Photobacterium sp. MBIC06485.   
J. Antibiot. 2008, 61, 11–17. 
52.  de Nys, R.; Kumar, N.; Sharara, K.A.; Srinivasan, S.; Ball, G.; Kjelleberg, S. A new metabolite 
from the marine bacterium Vibrio angustum S14. J. Nat. Prod. 2001, 64, 531–532. 
53.  Matsuura, S.; Odaka, M.; Sugimoto, T.; Goto, T. Structure of pteridines from Photobacterium 
phosphorium. Chem. Lett. 1973, 2, 343–346. 
54.  Suzuki, A.; Goto, M. Photolumazines, new naturally occurring inhibitors of riboflavin synthetase. 
Biochim. Biophys. Acta 1973, 313, 229–234. 
55.  Diep, B.A.; Gill, S.R.; Chang, R.F.; Phan, T.H.; Chen, J.H.; Davidson, M.G.; Lin, F.; Lin, J.; 
Carleton, H.A.; Mongodin, E.F.; Sensabaugh, G.F.; Perdreau-Remington, F. Complete genome 
sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus 
aureus. Lancet 2006, 367, 731–739. 
56.  Li, M.; Diep, B.A.; Villaruz, A.E.; Braughton, K.R.; Jiang, X.F.; Deleo, F.R.; Chambers, H.F.;  
Lu, Y.; Otto, M. Evolution of virulence in epidemic community-associated methicillin-resistant 
Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2009, 106, 5883–5888. 
57. Cao, J.G.; Meighen, E.A. Purification and structural identification of an autoinducer for the 
luminescence system of Vibrio harveyi. J. Biol. Chem. 1989, 264, 21670–21676. 
58.  Chen, X.; Schauder, S.; Potier, N.; Van Dorsselaer, A.; Pelczer, I.; Bassler, B.L.; Hughson, F.M. 
Structural identification of a bacterial quorum-sensing signal containing boron. Nature 2002, 415, 
545–549. 
59.  Higgins, D.A.; Pomianek, M.E.; Kraml, C.M.; Taylor, R.K.; Semmelhack, M.F.; Bassler, B.L. 
The major vibrio cholerae autoinducer and its role in virulence factor production. Nature 2007, 
450, 883–886. 
60. Kuo, A.; Blough, N.V.; Dunlap, P.V. Multiple N-Acyl-L-homoserine lactone autoinducers of 
luminescence in the marine symbiotic bacterium Vibrio fischeri. J. Bacteriol. 1994, 176, 7558–7565. 
61. Milton, D.L.; Hardman, A.; Camara, M.; Chhabra, S.R.; Bycroft, B.W.; Stewart, G.S.A.B.; 
Williams, P. Quorum sensing in Vibrio anguillarum: Characterization of the VanI/VanR locus 
and identification of the autoinducer N-(3-Oxodecanoyl)-L-homoserine lactone. J. Bacteriol. 
1997, 179, 3004–3012. 
62.  Schaefer, A.L.; Greenberg, E.P.; Oliver, C.M.; Oda, Y.; Huang, J.J.; Bittan-Banin, G.; Peres, C.M.; 
Schmidt, S.; Juhaszova, K.; Sufrin, J.R.; Harwood, C.S. A new class of homoserine lactone 
quorum-sensing signals. Nature 2008, 454, 595–599. 
63.  Dobretsov, S.; Teplitski, M.; Paul, V. Mini-review: Quorum sensing in the marine environment 
and its relationship to biofouling. Biofouling 2009, 25, 413–427. 
64. Harraghy, N.; Kerdudou, S.; Herrmann, M. Quorum-sensing systems in staphylococci as 
therapeutic targets. Anal. Bioanal. Chem. 2007, 387, 437–444. Mar. Drugs 2011, 9  
 
 
2552
65. Otto, M. Quorum-sensing control in staphylococci—A target for antimicrobial drug therapy. 
FEMS Microbiol. Lett. 2004, 241, 135–141. 
66.  Boles, B.R.; Horswill, A.R. agr-mediated dispersal of Staphylococcus aureus biofilms.  PLoS 
Pathog. 2008, 4, 1–13. 
67.  Defoirdt, T.; Boon, N.; Bossier, P. Can bacteria evolve resistance to quorum sensing disruption. 
PLoS Pathog. 2010, 6, 1–6. 
68.  Köhler, T.; Perron, G.G.; Buckling, A.; van Delden, C. Quorum sensing inhibition selects for 
virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 2010, 6, 1–6. 
69. Rumbaugh, K.P.; Diggle, S.P.; Watters, C.M.; Ross-Gillespie, A.; Griffin, A.S.; West, S.A. 
Quorum sensing and social evolution of bacterial virulence. Curr. Biol. 2009, 19, 341–345. 
70.  Ostling, J.; Goodman, A.; Kjelleberg, S. Behavior of incp-1 plasmids and a minimu transposon in 
a marine Vibrio sp.—Isolation of starvation inducible lac operon fusions. FEMS Microbiol. Ecol. 
1991, 86, 83–94. 
71.  Wietz, M.; Mansson, M.; Gram, L. Chitin stimulates production of the antibiotic andrimid in a 
Vibrio coralliilyticus strain. Environ. Microbiol. Rep. 2011, 3, 559–564. 
72.  Weyland, H.; Ruger, H.-J.; Schwarz, H. Zur Isolierung und identifizierung mariner bakterien. Ein 
beitrag zur standardisierung und entwicklung adaequater methoden. Veroff. Inst. Meeresforsch. 
Bremerh. 1970, 12, 269–296. 
73.  Hjelm, M.; Bergh, O.; Riaza, A.; Nielsen, J.; Melchiorsen, J.; Jensen, S.; Duncan, H.; Ahrens, P.; 
Birkbeck, H.; Gram, L. Selection and identification of autochthonous potential probiotic bacteria 
from turbot larvae (Scophthalmus maximus) rearing units. Syst. Appl. Microbiol. 2004, 27, 360–371. 
74.  Fujii, K.; Ikai, Y.; Oka, H.; Suzuki, M.; Harada, K. A nonempirical method using LC/MS for 
determination of the absolute configuration of constituent amino acids in a peptide: Combination 
of marfey’s method with mass spectrometry and its practical application. Anal. Chem. 1997, 69, 
5146–5151. 
75.  Bonnard, I.; Manzanares, I.; Rinehart, K.L. Stereochemistry of kahalalide F. J. Nat. Prod. 2003, 
66, 1466–1470. 
76.  Dale, J.A.; Dull, D.L.; Mosher, H.S. Alpha-methoxy-alpha-trifluoromethylphenylacetic acid, a 
versatile reagent for determination of enantiomeric composition of alcohols and amines. J. Org. 
Chem. 1969, 34, 2543–2549. 
77.  Sullivan, G.R.; Dale, J.A.; Mosher, H.S. Correlation of configuration and f-19 chemical-shifts of 
alpha-methoxy-alpha-trifluoromethylphenylacetate derivatives. J. Org. Chem. 1973, 38, 2143–2147. 
78.  Jelsbak, L.; Ingmer, H.; Valihrach, L.; Cohn, M.T.; Christiansen, M.H.G.; Kallipolitis, B.H.; 
Frees, D. The chaperone clpx stimulates expression of Staphylococcus aureus protein a by rot 
dependent and independent pathways. PLoS One 2010, 5, e12752:1–e12752:11. 
79.  Tenover, F.C.; Goering, R.V. Methicillin-resistant Staphylococcus aureus strain USA300: Origin 
and epidemiology. J. Antimicrob. Chemother. 2009, 64, 441–446. 
Samples Availability: Available from the authors. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 